The OptiShunt is LIQID Medical's flagship device
The device creates a shunt communication between the fluid chamber inside the eye and another fluid chamber located directly behind the eye. By leveraging this naturally occurring fluid reservoir, the OptiShunt is able to provide highly effective intraocular pressure (IOP) control without the costs and complications associated with traditional devices.
The OptiShuntV1 is a proof of concept device designed to evaluate the safety, feasibility, and efficacy of patented technology for the treatment of glaucoma.
The device is manufactured using world-class silicone micro moulding techniques according to ISO13485 guidelines and includes a custom shunt insertion system. Clinical trials are currently underway in the GOSSIP study being conducted at Groote Schuur tertiary academic Hospital, the home of the world’s first heart transplant.
GOSSIP Study Results
The Glaucoma treatment by OculoSubarachnoid Shunt Insertion Pilot (GOSSIP) study is an early feasibility study evaluating the safety and feasibility of the OptiShunt. The study is conducted according to GCP and ISO14155 guidelines.
Twelve-month trial results demonstrate that the OptiShunt device is highly effective in the treatment of severe and refractory glaucoma. The intraocular pressure (IOP) lowering effect of the OptiShunt was demonstrated to be at least 50% more effective than the current gold standard over the course of twelve months.
Average IOP following OptiShunt implantation
The OptiShuntV2 is the follow-on device which incorporates design optimisation changes and is set for clinical trials kicking off in January 2022.
The device includes a two-part construction and an upgraded shunt insertion system to make the device simpler, safer, and even more effective.